Robust kinetic model for quantification of P-glycoprotein (P-gp) function under altered metabolism and after P-gp inhibition using (R)[C-11]verapamil and PET

被引：0
|
作者：
Wang, Shaonan [1 ]
Feldmann, Maria [2 ]
Hinz, Rainer [1 ]
McMahon, Adam [1 ]
Koepp, Matthias [2 ]
Jackson, Alan [1 ]
Asselin, Marie-Claude [1 ]
机构：
[1] Univ Manchester, Sch Canc & Enabling Sci, Wolfson Mol Imaging Ctr, Manchester M13 9PL, Lancs, England
[2] UCL, Inst Neurol, London WC1E 6BT, England
来源：
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM | 2012年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S169 / S170
页数：2
相关论文
共 50 条
  • [21] Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp)
    Schmitt, U.
    Abou El-Ela, A.
    Guo, L. J.
    Glavinas, H.
    Krajcsi, P.
    Baron, J. M.
    Tillmann, C.
    Hiemke, C.
    Langguth, P.
    Haertter, S.
    JOURNAL OF NEURAL TRANSMISSION, 2006, 113 (07) : 787 - 801
  • [22] Ultrafast mass spectrometry based bioanalytical method for digoxin supporting an in vitro P-glycoprotein (P-gp) inhibition screen
    Wagner, Andrew D.
    Kolb, Janet M.
    Oezbal, Can C.
    Herbst, John J.
    Olah, Timothy V.
    Weller, Harold N.
    Zvyaga, Tatyana A.
    Shou, Wilson Z.
    RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2011, 25 (09) : 1231 - 1240
  • [23] Functional implication of p-glycoprotein (P-gp) modulation on the intraocular disposition of its substrate using intravitreal microdialysis
    Velpandian, T.
    Senthilkumari, S.
    Biswas, N. R.
    Saxena, R.
    Ghose, S.
    INDIAN JOURNAL OF PHARMACOLOGY, 2008, 40 : 198 - 198
  • [24] Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp)
    U. Schmitt
    A. Abou El-Ela
    L. J. Guo
    H. Glavinas
    P. Krajcsi
    J. M. Baron
    C. Tillmann
    C. Hiemke
    P. Langguth
    S. Härtter
    Journal of Neural Transmission, 2006, 113 : 787 - 801
  • [25] Kinetic modeling of [11C]laniquidar in human brain - A novel PET tracer for P-gp expression
    Postnov, Andre
    Froklage, F.
    Boellaard, Ronald
    Schuit, Robert
    Eriksson, Jonas
    Windhorst, Albert
    Voskuyl, Rob
    van Berckel, Bart
    Lammertsma, Adriaan
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [26] Inhibition of CYP3A4 metabolism and P-glycoprotein efflux by PTP-112: Evaluation of different P-GP probe substrates
    Oganesian, A
    Tran, J
    Turner, S
    Talaat, R
    Leung, L
    DRUG METABOLISM REVIEWS, 2003, 35 : 148 - 148
  • [27] The disposition of [14C]saquinavir in normal and P-glycoprotein (P-gp) deficient mice and cultured cells.
    Washington, CB
    Man, MC
    Moy, T
    Blaschke, TE
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 181 - 181
  • [28] Use of the rat as a model to assess the potential for clinical drug-drug interactions involving P-glycoprotein (P-gp)
    Chong, SH
    Yao, M
    Zhang, HJ
    DRUG METABOLISM REVIEWS, 2004, 36 : 59 - 59
  • [29] Tariquidar inhibition of P-glycoprotein activity in patients with temporal lobe epilepsy measured with PET and (R)-[C-11]Verapamil
    Feldmann, Maria
    Asselin, Marie-Claude
    Wang, Shaonan
    McMahon, Adam
    Walker, Matthew
    Anton, Jose
    Hinz, Rainer
    Sisodiya, Sanjay
    Duncan, John
    Koepp, Matthias
    NEUROIMAGE, 2010, 52 : S148 - S148
  • [30] Using PET Studies of P-gp Function to Elucidate Mechanisms Underlying the Disposition of Drugs
    Syvanen, Stina
    Hammarlund-Udenaes, Margareta
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2010, 10 (17) : 1799 - 1809
12345